X
Xilio Therapeutics, Inc. (XLO)
NCM – Real vaqt narxi. Valyuta: USD
7.73
0.00 (0.00%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
7.73
0.00 (0.00%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Xilio Therapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, niqoblangan immuno-onkologiya terapiyalarini kashf qilish va ishlab chiqish bilan shug'ullanadi. Kompaniyaning portfelida metastatik mayda hujayrali o'pka saratoni bilan og'rigan bemorlar uchun PD-1 / niqoblangan IL-2 bo'lgan XTX501; ilg'or qattiq o'smalari bo'lgan bemorlar uchun 2-bosqichli klinik sinovlarda bo'lgan tadqiqotdagi, niqoblangan IL-12 bo'lgan Efarindodekin alfa; va CTLA-4 ga qarshi tadqiqotdagi, o'sma tomonidan faollashtiriladigan, Fc bilan kuchaytirilgan, yuqori affinlikli bog'lanuvchi monoklonal antitelosi bo'lgan Vilastobart mavjud. Kompaniya 2016-yilda tashkil etilgan va shtab-kvartirasi Uolthem, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Katarina Luptakova M.D. | Chief Medical Officer |
| Dr. Rene Russo BCPS, Pharm.D. | President, CEO & Director |
| Dr. Scott Coleman Ph.D. | Chief Development Officer |
| Dr. Uli Bialucha Ph.D. | Chief Scientific Officer |
| Mr. Christopher Frankenfield | CFO & COO |
| Mr. Kevin M. Brennan | Senior Vice President of Finance & Accounting |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-12 | S-3 | xlo-20260512.htm |
| 2026-04-28 | ARS | 2026_04_28_-_ars.pdf |
| 2026-04-16 | 8-K | xlo-20260416.htm |
| 2026-03-23 | S-8 | xlo-20260323.htm |
| 2026-03-23 | 8-K | xlo-20260323.htm |
| 2026-03-12 | 8-K | xlo-20260312.htm |
| 2026-03-09 | 8-K | xlo-20260309.htm |
| 2026-02-24 | 8-K | xlo-20260223.htm |
| 2026-02-12 | 8-K | d85184d8k.htm |
| 2026-01-26 | DEF 14A | xlo-20260122.htm |
| Mr. Nathan McBride | Chief Information Officer |
| Ms. Caroline Hensley | Chief Legal Officer |
| Ms. Ruth du Moulin | Senior Vice President of Medical Affairs |